000284085 001__ 284085
000284085 005__ 20260126110609.0
000284085 0247_ $$2doi$$a10.3389/fimmu.2019.03120
000284085 037__ $$aDZNE-2026-00093
000284085 041__ $$aEnglish
000284085 082__ $$a610
000284085 1001_ $$aGonçalves, William Antonio$$b0
000284085 245__ $$aSensory Ganglia-Specific TNF Expression Is Associated With Persistent Nociception After Resolution of Inflammation
000284085 260__ $$aLausanne$$bFrontiers Media$$c2020
000284085 3367_ $$2DRIVER$$aarticle
000284085 3367_ $$2DataCite$$aOutput Types/Journal article
000284085 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769421922_1866
000284085 3367_ $$2BibTeX$$aARTICLE
000284085 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284085 3367_ $$00$$2EndNote$$aJournal Article
000284085 520__ $$aJoint pain is a distressing symptom of arthritis, and it is frequently persistent even after treatments which reduce local inflammation. Continuous production of algogenic factors activate/sensitize nociceptors in the joint structures and contribute to persistent pain, a challenging and difficult condition to treat. TNF is a crucial cytokine for the pathogenesis of several rheumatic diseases, and its inhibition is a mainstay of treatment to control joint symptoms, including pain. Here, we sought to investigate the inflammatory changes and the role of TNF in dorsal root ganglia (DRG) during persistent hypernociception after the resolution of acute joint inflammation. Using a model of antigen-induced arthritis, the peak of joint inflammation occurred 12-24 h after local antigen injection and was characterized by an intense influx of neutrophils, pro-inflammatory cytokine production, and joint damage. We found that inflammatory parameters in the joint returned to basal levels between 6 and 8 days after antigen-challenge, characterizing the resolving phase of joint inflammation. Mechanical hyperalgesia was persistent up to 14 days after joint insult. The persistent nociception was associated with the inflammatory status of DRG after cessation of acute joint inflammation. The late state of neuroinflammation in the ipsilateral side was evidenced by gene expression of TNF, TNFR2, IL-6, IL-1β, CXCL2, COX2, and iNOS in lumbar DRG (L3-L5) and leukocyte adhesion in the lumbar intumescent vessels between days 6 and 8. Moreover, there were signs of resident macrophage activation in DRG, as evidenced by an increase in Iba1-positive cells. Intrathecal or systemic injection of etanercept, an agent clinically utilized for TNF neutralization, at day 7 post arthritis induction, alleviated the persistent joint hyperalgesia by specific action in DRG. Our data suggest that neuroinflammation in DRG after the resolution of acute joint inflammation drives continuous neural sensitization resulting in persistent joint nociception in a TNF-dependent mechanism.
000284085 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000284085 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000284085 650_7 $$2Other$$aTNF
000284085 650_7 $$2Other$$aarthritis
000284085 650_7 $$2Other$$adorsal root ganglia
000284085 650_7 $$2Other$$aneuroinflammation
000284085 650_7 $$2Other$$apain
000284085 650_7 $$2Other$$aresolution of inflammation
000284085 650_7 $$2NLM Chemicals$$aBiomarkers
000284085 650_7 $$2NLM Chemicals$$aTumor Necrosis Factor-alpha
000284085 650_2 $$2MeSH$$aAnimals
000284085 650_2 $$2MeSH$$aArthralgia: etiology
000284085 650_2 $$2MeSH$$aArthralgia: metabolism
000284085 650_2 $$2MeSH$$aArthralgia: pathology
000284085 650_2 $$2MeSH$$aBiomarkers
000284085 650_2 $$2MeSH$$aBiopsy
000284085 650_2 $$2MeSH$$aDisease Models, Animal
000284085 650_2 $$2MeSH$$aDisease Susceptibility
000284085 650_2 $$2MeSH$$aGanglia, Spinal: metabolism
000284085 650_2 $$2MeSH$$aGene Expression
000284085 650_2 $$2MeSH$$aInflammation: etiology
000284085 650_2 $$2MeSH$$aInflammation: metabolism
000284085 650_2 $$2MeSH$$aInflammation: pathology
000284085 650_2 $$2MeSH$$aMale
000284085 650_2 $$2MeSH$$aMice
000284085 650_2 $$2MeSH$$aNociception
000284085 650_2 $$2MeSH$$aSpinal Cord
000284085 650_2 $$2MeSH$$aTumor Necrosis Factor-alpha: genetics
000284085 650_2 $$2MeSH$$aTumor Necrosis Factor-alpha: metabolism
000284085 7001_ $$aRezende, Barbara Maximino$$b1
000284085 7001_ $$aOliveira, Marcos Paulo Esteves de$$b2
000284085 7001_ $$0P:(DE-2719)9001782$$aSecchim Ribeiro, Lucas$$b3$$udzne
000284085 7001_ $$aFattori, Victor$$b4
000284085 7001_ $$aSilva, Walison Nunes da$$b5
000284085 7001_ $$aPrazeres, Pedro Henrique Dias Moura$$b6
000284085 7001_ $$aQueiroz-Junior, Celso Martins$$b7
000284085 7001_ $$aSantana, Karina Talita de Oliveira$$b8
000284085 7001_ $$aCosta, Walyson Coelho$$b9
000284085 7001_ $$aBeltrami, Vinícius Amorim$$b10
000284085 7001_ $$aCosta, Vivian Vasconcelos$$b11
000284085 7001_ $$aBirbrair, Alexander$$b12
000284085 7001_ $$aVerri, Waldiceu A.$$b13
000284085 7001_ $$aLopes, Fernando$$b14
000284085 7001_ $$aCunha, Thiago Mattar$$b15
000284085 7001_ $$aTeixeira, Mauro Martins$$b16
000284085 7001_ $$aAmaral, Flávio Almeida$$b17
000284085 7001_ $$aPinho, Vanessa$$b18
000284085 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2019.03120$$gVol. 10, p. 3120$$p3120$$tFrontiers in immunology$$v10$$x1664-3224$$y2020
000284085 8564_ $$uhttps://pub.dzne.de/record/284085/files/fimmu-10-03120.pdf$$yOpenAccess
000284085 8564_ $$uhttps://pub.dzne.de/record/284085/files/fimmu-10-03120.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000284085 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001782$$aExternal Institute$$b3$$kExtern
000284085 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000284085 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000284085 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000284085 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-29T15:23:07Z
000284085 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-29T15:23:07Z
000284085 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000284085 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-29T15:23:07Z
000284085 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000284085 915__ $$0StatID:(DE-HGF)10000$$2StatID$$aHosted Content
000284085 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000284085 920__ $$lyes
000284085 980__ $$ajournal
000284085 980__ $$aI:(DE-2719)1040260
000284085 9801_ $$aUNRESTRICTED
000284085 9801_ $$aEXTERN4VITA
000284085 9801_ $$aFullTexts